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Abstract
I In nt tr ro od du uc ct ti io on n: :   The aim of our study was to analyse the efficacy and safety of
mycophenolate mofetil (MMF) as part of the complex immunosuppressive ther-
apy in children with different types of primary and secondary glomerulonephritis,
who were not eligible for the standard treatment routine suggested by evidence-
based guidelines. 
M Ma at te er ri ia al l   a an nd d   m me et th ho od ds s: :   The study group comprised 85 children with proteinuric
glomerulopathies hospitalized between 2007 and 2010, who were non-respon-
ders to immunosuppressive therapy. The dose of MMF was established as
1 g/m2/24 h. Remission was defined as negative proteinuria in three consecu-
tive urinalyses.
R Re es su ul lt ts s: :   The patients were divided into 4 groups: idiopathic nephrotic syndrome
(n = 35), primary glomerulonephritis (n = 15), auto-antibody associated glomeru-
lonephritis (n = 20) and lupus nephropathy (LN, n = 15). Ten patients from the
first group (29%) and 5 patients each from the second and third group (34% and
25% respectively) did not respond to MMF therapy. On the other hand, all the
children diagnosed with LN have reached clinical and biochemical remission. 
C Co on nc cl lu us si io on ns s: :   Alternative rescue MMF therapy should always be taken into con-
sideration  in  proteinuric  patients  who  are  non-responders  to  steroids,
cyclosporine A and cyclophosphamide in whom the initial glomerular filtration
rate is higher than 60 ml/min/1.73m2. It is recommended that MMF be admin-
istered as part of the standard treatment regimen in patients diagnosed with
lupus nephropathy. In these groups of patients, the potent benefits of this ther-
apy are higher than expected side-effects.
K Ke ey y   w wo or rd ds s: :   mycophenolate mofetil, nephrotic syndrome, outcome, paediatrics.
Introduction
Proteinuria is currently regarded as one of the most important factors
impairing kidney function, inducing an inflammatory sequence within renal
parenchyma and progressing to end-stage renal disease (failure) [1]. In
children, idiopathic nephrotic syndrome (INS) is the most common cause
of massive proteinuria, resulting inter alia in low concentration of serum
albumin and hypercholesterolaemia [2]. Clinically these factors give rise
to nephrotic syndrome, which is mainly characterized by generalized oede-
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ma, thrombosis, and metabolic abnormalities such
as hypocalcaemia and hypothyroidism, which are
the consequence of albumin loss [3]. The most fre-
quent histological form of INS is minimal change
disease (MCD) and focal segmental glomeruloscle-
rosis (FSGS) [4]. Furthermore, in paediatric renal
biopsies of INS children, mesangial hypercellulari-
ty (MH) can be diagnosed [5]. None of these histo-
logical forms are accompanied by immunological
deposit formation evaluated by electron microscopy
or in immunofluorescence studies. Among differ-
ent types of secondary glomerulonephritis, systemic
lupus erythematosus (SLE) is judged as the most
hazardous cause of secondary glomerulopathy in
teenagers [6]. Other causes of secondary glomeru-
lonephritis, for example associated with anti-neu-
trophil cytoplasmic antibodies dependent vasculi-
tis and bronchial asthma (Churg-Strauss syndrome),
are less frequent in children but, similarly, are asso-
ciated with unfavourable prognosis [7, 8].
The immunosuppressive therapy strategy in INS
regularly starts with glucocorticosteroids (GC).
Recent reports indicate that more than 90% of pae-
diatric patients with INS respond to this therapy
(steroid-sensitive INS) [3]. Unfortunately, steroid-
dependent or steroid-resistant NS impels clinicians
to introduce cyclophosphamide and/or calcineurin
inhibitors [9-11]. This nature of INS remains a chal-
lenge for clinicians to achieve successful induction
and maintenance of complete remission in nephrot-
ic syndrome.
In SLE dependent nephropathy the therapy pro-
cedure follows the clinical course and histological
classification of renal biopsies, and is based on the
well-experienced complexity of multi-drug immuno-
suppression [12, 13]. On the other hand, some of
the primary as well as secondary glomerulopathies
(e.g. Churg-Strauss syndrome) intricate by nephrot-
ic-range proteinuria require parallel GC and option-
al immunosuppressive therapy (cyclophosphamide
and/or azathioprine) determined by validated prog-
nostic criteria (Five Factor Score) [8]. 
However, considerable toxicity of the above-men-
tioned procedure and inadequate clinical response
to this therapy compelled us to search for more
effective and safe treatment. 
Mycophenolate mofetil (MMF) is an immuno-
suppressive agent, which is metabolized in the liv-
er to the active moiety mycophenolic acid. It inhibits
inosine  monophosphate  dehydrogenase,  the
enzyme that controls the rate of biosynthesis of
guanine monophosphate in the de novo pathway
of purine synthesis used in the proliferation of 
B and T lymphocytes, and mesangial cells [14].
According to some preliminary reports, MMF can
be used not only in solid-organ transplantation but
also as an alternative immunosuppressive therapy,
in proteinuric nephropathies [15-17]. 
In line with the above, the aim of our study was
to analyse the efficacy and safety of MMF as part
of the complex immunosuppressive therapy in chil-
dren with different types of primary and secondary
glomerulonephritis, who were not eligible for the
standard treatment routine suggested by evidence-
based guidelines.
Material and methods
P Pa at ti ie en nt t   p po op pu ul la at ti io on n
Patients who were aged 2 to 18 years were eli-
gible for entry into this study when they had evi-
dence of either steroid-resistant NS (SRNS), steroid-
dependent NS (SDNS) or frequently relapsing NS
(FRNS). Relapse of NS before study entry was
defined as proteinuria ≥ 2+ by dipstick for 3 or more
consecutive days or recurrence of sufficient clinical
features of NS to prompt therapy with daily steroids
by the attending physician. 
Steroid-resistant NS was defined in patients who
failed to respond to a 4 + 4 week course of steroid
(prednisolone 60 mg per m2/day for 4 weeks, fol-
lowed by 40 mg/m2 three times a week for 4 weeks
in the 6 months before entry). Steroid-dependent
NS was defined in patients who had a relapse of
NS after a decrease in the dosage of prednisone or
within 28 days of stopping prednisone on two or
more consecutive occasions in the 12 months
before entry. One of these episodes must have been
within 3 months before entry). Frequently relaps-
ing NS was defined in patients who responded to
prednisone treatment but who had four or more
relapses within the 12 months before the screen-
ing visit or two or more relapses within the first 6
months after the initial response (if this was in the
6 months before entry). 
Patients were allowed to receive a course of
cyclophosphamide or chlorambucil in the past but
again had to satisfy the entry criteria for steroid
dependence and/or FRNS after the course of cyto-
toxic medication was completed. Female patients
of childbearing potential were required to have
a negative pregnancy test < 1 week before starting
MMF. Such patients had to agree to use two reli-
able forms of contraception simultaneously before
beginning study drug therapy, during therapy, and
for 6 weeks after discontinuation of study drug ther-
apy. 
Exclusion criteria that were used in the study
included the following: absolute neutrophil count
< 4 G/l; haematocrit < 0.25; history of significant
gastrointestinal disorder; active systemic infection
or history of serious infection within 1 month of
entry; known infection with HIV or the presence of
hepatitis B surface antigen; other major organ sys-
tem disease or malignancy; administration of live
viral vaccine within 6 weeks before study entry; and
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current or recent (within 30 days) exposure to any
investigational drug. 
The study group comprised 85 children with pro-
teinuric glomerulopathies hospitalized between
2007  and  2010,  who  were  non-responders  to
immunosuppressive therapy. They were admitted
to the Department of Paediatric Cardiology and
Nephrology, Poznan University of Medical Sciences
in Poland. Forty-five boys (aged 12.2 ﾱ6.3 years) and
forty girls (aged 11.9 ﾱ7.4 years) underwent a renal
biopsy according to the International Study for Kid-
ney Disease in Children recommendations [18, 19].
These indications included steroid-resistant NS
(SRNS,  n  =  11),  steroid-dependent  NS  (SDNS, 
n = 14), frequently relapsing NS (FRNS, n = 10), pri-
mary glomerulonephritis (n = 16), auto-antibody
associated glomerulonephritis (AAGN, n = 19) and
lupus nephropathy (LN; n = 15). According to WHO
definitions, histological evaluation of the study
group revealed the following: diffuse mesangial pro-
liferation (DMP, n = 15), focal segmental glomeru-
losclerosis  (FSGS,  n  =  20),  glomerulosclerosis 
(GS, n = 25), primary mesangial glomerulonephri-
tis (PMG, n = 10) and, finally, lupus nephropathy 
(n = 15) [20]. Diffuse mesangial proliferation diag-
nosis was based on the number of cells visible
under the electron microscope per mesangial area.
INS was classically characterized by the absence 
of significant deposits in immunofluorescence
microscopy, except for FSGS and sclerotic lesions,
which were found to bind IgM and C3 antiserum
without  electron-dense  deposits  [5].  No  IgA
nephropathy was diagnosed in the studied popu-
lation. Detailed information is shown in Table I.
Since MMF is not yet approved for convention-
al therapy administered in different proteinuric
glomerulopathies in Poland [15], we obtained the
necessary approval from the Polish Health Depart-
ment, which authorized MMF use in this group of
children. Equally, the study protocol was ratified by
the local Ethics Committee of Poznan University of
Medical Sciences, and the parents of the study par-
ticipants gave written, informed consent for the
investigation. The study fulfilled the standards rec-
ommended by the Helsinki convention. 
T Tr re ea at tm me en nt t   p pr ro ot to oc co ol l
The  dose  of  MMF  was  established  as
1 g/m2/24 h in two therapeutic doses given pre-
cisely at 7 am and 7 pm. This daily dose was then
modified according to the clinical course of pro-
teinuric glomerulopathies. Because there is still no
possibility to evaluate plasma concentration of
MMF and its metabolites in our department, we
carefully studied all the possible clinical side effects,
and checked complete blood morphology as well
as plasma renal and liver markers to detect any
changes necessitating prompt drug withdrawal.
According to Bagga et al., all the patients treated
with MMF were additionally given prednisolone 0.5
mg/kg/48 h [21]. Remission was defined as absence
of proteinuria (urine albumin nil or trace for three
consecutive days by dipstick or boiling test).
F Fo ol ll lo ow w- -u up p   a an nd d   s sa af fe et ty y   a as ss se es ss sm me en nt t
The more precise patient status was evaluated
at the time: zero, 3, 6, 12, 18 and 24 (when applica-
ble) months starting from the beginning of MMF
therapy. At each follow-up visit, not only clinical sta-
tus, but also blood pressure, complete blood mor-
phology including white blood cell count (WBC),
serum creatinine, glomerular filtration rate (GFR),
electrolytes, lipid profile, bilirubin and liver enzymes
(alanine aminotransferase, aspartate aminotrans-
ferase), glycaemia and 24-h urinary protein excre-
tion were recorded. Study participants were also
monitored for the presence of viral infections (HBV,
HCV, EBV and BKV). In addition, in patients diag-
nosed with LN as well as patients recognized with
GN associated with ANCA positive antibodies the
serum concentrations of auto-antibodies (anti-ANA,
anti-dsDNA, anti-cardiolipin and anti-ANCA) were
checked every third month. Each infectious episode
was systematically assessed and followed by micro-
biological tests of blood, sputum or broncho-alve-
olar lavage and urine analysis (culture). The treat-
ment protocol was arrested in all the patients who
developed leucopenia (WBC < 4 G/l). These children
were transitionally given only GC and were includ-
ed back in the treatment protocol when WBC was
estimated > 4 G/l in three subsequent blood analy-
ses.
S St ta at ti is st ti ic ca al l   a an na al ly ys si is s
Data are expressed as mean ﾱ SD unless other-
wise stated. A Wilcoxon ranks test was applied to
determine whether there was a significant change
in relapse rate before and after therapy with MMF.
Two variables (proteinuria and GFR) in all the
patients were analysed at time zero (at the begin-
ning of the study) as well as at 3, 6, 12, 18 and 24
months of MMF therapy using Spearman's rank cor-
relation coefficient (Spearman's rho). Significance
was set as p < 0.05; statistical analysis was per-
formed using Statistica 8.0 PL software. 
Results
Patients were divided into four groups: idiopathic
nephrotic syndrome (n = 35), primary glomeru-
lonephritis  (n =  15),  auto-antibody  associated
glomerulonephritis (n = 20) and lupus nephropathy
(n = 15). Ten patients from the first group (29%)
and 5 patients from the second as well as the third
group (33.3% and 25% respectively) did not respond
to MMF therapy. On the other hand, all the children
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diagnosed with LN reached clinical and biochemi-
cal remission (p < 0.05 as compared to the former
three groups). Non-respondent subjects progressed
to ESRD (15 children needed renal replacement ther-
apy) and five patients expressed the next relapse
of nephrotic syndrome which needed cyclosporine
A therapy to achieve remission. These children were
sex and age independent.
Interestingly, 15/25 (60%) children, who were rec-
ognized with glomerulosclerosis in renal biopsy
evaluation, did not respond to MMF therapy. These
children also had a significantly lower GFR as com-
pared to the rest of patients, who achieved remis-
sion secondary to MMF administration. 
Eighteen patients required a 25% MMF dose
increase to obtain remission. They were enrolled
from the idiopathic nephrotic syndrome group 
(n = 9), and primary glomerulonephritis (n = 5) and
auto-antibody associated GN (n = 4). Again, LN chil-
dren did not need MMF dose alteration. The neces-
sity of MMF dose increase was independent of age,
sex, initial histology or GFR. It was exclusively relat-
ed to the clinical course, during which patients who
did not respond to the initial MMF dose could be
given a higher therapeutic dose.
As regards the previous therapeutic regimens
given to our patients prior to MMF commencement,
the majority of patients received prednisolone,
methylprednisolone,  cyclophosphamide  and
cyclosporine A treatment. Individuals were addi-
tionally given tacrolimus and underwent plasma-
pheresis. 
The most common MMF side-effect was frequent
viral infection of the upper respiratory tract. That
inconvenience affected 53% of children and was
independent of MMF dose. The second common
side-effect was irregular (episodic) leucopenia. It was
diagnosed in 24% of subjects, but first of all referred
to LN patients. In a single patient diagnosed with
Churg-Strauss syndrome, a constant and chronic
leucopenia (over 3 months) was the main side-effect
and, consequently, the reason for discontinuation
of MMF therapy. That boy, regardless of the benefi-
cial MMF effect on kidney function (GFR improved
from 75 ml/min/1.73 m2 to 94 ml/min/1.73 m2), was
the last subject, besides MMF non-responders, who
stopped MMF treatment.
Initially, before commencement of MMF treat-
ment, proteinuria was observed in 65/85 patients
(76.5%) (proteinuria exceeded 50 mg/kg/24 h in
44/65 patients (67.7%). During the MMF treatment
protocol this sign of kidney failure decreased grad-
ually and finally was absent in the study partici-
pants with the exception of 19 children (including
15 patients in whom MMF therapy was arrested).
Spearman’s correlation of proteinuria and MMF
treatment time was significant (r = –0.575; p < 0.01;
Figure 1).
On the other hand, twenty children were esti-
mated to have GFR less than 60 ml/min/1.73 m2.
During the MMF treatment strategy, fifteen of them
progressed to ESRD (non-effective rescue therapy;
all with glomerulosclerosis), whereas 5 of them
showed improvement of kidney function as evi-
denced by normal GFR and achieved remission with
no proteinuria. Again, Spearman’s correlation of 
GFR and MMF treatment period was significant 
(r = 0.293; p < 0.05; Figure 2). 
Discussion
Our challenge to summarize the results of MMF
therapy in children with different primary and sec-
ondary glomerulonephritides was due to the gen-
eral opinion that MMF could serve as an alterna-
tive  drug  in  the  non-responding  proteinuric
nephropathy treatment regimen [11, 13, 15, 21].
Mycophenolate mofetil is one of the immuno-
suppressant drugs which have been used to pre-
180
160
140
120
100
80
60
40
20
0
–20
–2 02468 10 12 14 16 18 20 22 24 26
T Ti im me e   [ [m mo on nt th hs s] ]
F Fi ig gu ur re e   1 1. .   Proteinuria (mg/kg/24 h) in children with
primary and secondary glomerulonephritis during
MMF therapy
P
P
r
r
o
o
t
t
e
e
i
i
n
n
u
u
r
r
i
i
a
a
280
260
240
220
200
180
160
140
120
100
80
60
40
20
0
–20
–2 02468 10 12 14 16 18 20 22 24 26
T Ti im me e   [ [m mo on nt th hs s] ]
F Fi ig gu ur re e   2 2. .   GFR (ml/min/1.73 m2) of children with pri-
mary and secondary glomerulonephritis during MMF
therapy
G
G
F
F
R
R
Danuta Ostalska-Nowicka, Agnieszka Malinska, Magdalena Silska, Bartlomiej Perek, Jacek Zachwieja, Michal NowickiArch Med Sci 6, December / 2011 1047
vent rejection in organ transplantation. Generally
it is used as part of a three-compound regimen of
immunosuppressants,  including  a calcineurin
inhibitor (cyclosporine or tacrolimus) and pred-
nisolone.  As  an  immunosuppressant  that  has 
drastically decreased the incidence of acute rejec-
tion in solid transplant recipients, mycophenolate
is increasingly utilized as a steroid-sparing treat-
ment in immune-mediated disorders including
immunoglobulin A nephropathy, small vessel vas-
culitis as well as psoriasis [23, 24]. 
Its increasing application in LN treatment has
demonstrated more frequent complete response
and less frequent complications [25] as compared
to cyclophosphamide bolus therapy, a regimen with
risk of bone marrow suppression, infertility, and
malignancy [26]. Further work addressing mainte-
nance therapy showed mycophenolate to be supe-
rior  to  cyclophosphamide,  again  in  terms  of
response and side-effects [27]. Walsh et al. even
proposed that mycophenolate could be considered
as a first-line induction therapy for treatment of LN
in patients without renal dysfunction [28], sug-
gesting that mycophenolate will be encountered
more frequently in medical practice.
In our study, fifteen patients with LN were treat-
ed with MMF to induce remission (during the first
6 months of treatment). All of them expressed
remission of proteinuria. It cannot be excluded that
in some of the patients there was spontaneous
remission, although this is not a very common
occurrence.  All  of  the  children  with  LN  also
expressed a diminished number of leucocytes in
peripheral blood morphology with negative auto-
antibodies during immunosuppressive treatment.
This inconvenience was, however, episodic. 
We have demonstrated that the MMF treatment
regimen could also be beneficial in certain cases of
steroid and cyclosporine A dependent nephrotic
syndrome, primary glomerulonephritides, and auto-
antibody associated glomerulopathies. We postu-
late that such a treatment strategy should always
be taken into consideration in all patients in whom
a standard and recommended treatment protocol
fails. Mycophenolate mofetil administration usual-
ly generates less frequent and more gentle side-
effects. It should be re-considered even in patients
with initially low GFR, although the final decision
as regards its administration in that group of
patients should be evaluated after 3 months to 
6 months of treatment. Otherwise, expected bene-
fits could be less than progressive side-effects. 
Common adverse drug reactions associated with
mycophenolate therapy include diarrhoea, nausea,
vomiting, infections, leukopenia, and/or anaemia.
Mycophenolate mofetil is also believed to be com-
monly associated with fatigue, headache, and/or
cough [29]. Intravenous administration of MMF is
sometimes associated with thrombophlebitis and
thrombosis. Infrequent adverse effects (0.1-1% of
patients) include oesophagitis, gastritis, gastroin-
testinal  tract  haemorrhage,  and/or  invasive
cytomegalovirus (CMV) infection [30]. Our studied
children have primarily developed frequent viral
infections of the upper respiratory tract, which,
however were independent from leucopenia. Sin-
gle  leucopenic  episodes  were  observed  in  20
patients (including all LN subjects). A single child,
diagnosed  with  Churg-Strauss  syndrome,  had
chronic leucopenia which was augmented inde-
pendently from MMF dose. This only example of
severe leuco- and granulopenia could be related to
the basic problem of this patient, but naturally such
an observation would need further expanded stud-
ies. We did not observe any other side-effects as
listed above in the rest of patients, even when they
received the 25% higher dose of MMF.
In conclusion, we postulate that alternative res-
cue MMF therapy should always be taken into con-
sideration in proteinuric patients not responding to
steroids, cyclosporine A and cyclophosphamide in
whom the initial glomerular filtration rate is high-
er than 60 ml/min/1.73 m2. We recommend that
MMF be administered as part of the standard treat-
ment regimen in patients diagnosed with lupus
nephropathy. In this group of patients, the potent
benefits of this therapy are higher than expected
side-effects. 
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